Entrectinib for treating NTRK fusion-positive solid tumours

  • Technology appraisal guidance
  • TA644
  • Published: 

Information for the public

Entrectinib (Rozlytrek) is available through the Cancer Drugs Fund as a possible treatment for neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children 12 years and older if:

  • the disease is locally advanced or metastatic or surgery to remove the tumour could cause severe health problems
  • you have not had an NTRK inhibitor before and
  • you have no satisfactory treatment options.

More evidence on entrectinib is being collected, until there are enough data to address NICE’s uncertainties about the drug. After this NICE will decide whether or not to recommend entrectinib for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.

If you are not eligible for entrectinib but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about making decisions about your care.

Questions to think about

  • How well does it work compared with other treatments?
  • What are the risks or side effects? How likely are they?
  • How will the treatment affect my day-to-day life?
  • What happens if the treatment does not work?
  • What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The NHS website may be a good place to find out more.

These organisations can give you advice and support:

You can also get support from your local Healthwatch.

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-3841-4

This page was last updated: